Biopharmaceutical companies are incorporating medical-grade wearable sensors into Phase II and Phase III clinical trials to gather real-world physiological data.
Enhanced Data Fidelity
Continuous tracking of cardiovascular and metabolic metrics reduces reliance on periodic clinic visits. Researchers report higher statistical power and faster detection of adverse events, ultimately streamlining regulatory submission dossiers.
Regulatory Frameworks
Health authorities have published updated guidance accepting digital biomarkers, though data security and sensor calibration standards remain subject to strict audit protocols.